Detecting rare cells with nanoparticles
One of the most promising characteristics of nanoparticles as diagnostic agents is the ability to attach to the nanoparticles surface any of a wide variety of targeting molecules that can increase the distinction between malignant and healthy cells, making it easier to spot small numbers of diseased cells within a sea of healthy cells. However, the development of such targeted nanoparticles has been hampered by the need to optimize the chemical methods used to link the targeting molecule to the nanoparticle for each unique combination of the two.
Now, a team of investigators at the Massachusetts General Hospital and Harvard Medical School has developed a chemical methodology that can be used to attach virtually any antibody to a nanoparticle without the need to optimize the reaction conditions. This team, led by Ralph Weissleder, who is a co-principal investigator of the MIT-Harvard Center of Cancer Nanotechnology Excellence, published their findings in the journal Nature Nanotechnology.
Using a nanoparticle that is both magnetic and fluorescent and three different monoclonal antibodies known to target tumor-associated surface molecules, Dr. Weissleder and his collaborators applied what they call "bioorthogonal chemistry" to create nanoparticles that bind strongly to the targeted tumor types. They showed that binding took place with the proper cells using a novel miniaturized magnetic resonance detector system developed by the Weissleder team for use in point-of-care applications.
The investigators then compared the binding ability of their targeted nanoparticles with those prepared using one of the now-standard approaches for linking antibodies to nanoparticles. The new process created nanoparticles that stuck to their targeted cells with 10 to 15 times the avidity of those nanoparticles prepared with standard methods. In addition to improving the sensitivity of tumor cell detection using targeted nanoparticles, this new chemistry could also improve strategies for developing targeted drug delivery applications.
Source: National Cancer Institute /...
Previous Story: Nanoparticles behind new approach to cancer therapy
Next Story: Massive data storage through new BEANs
The Institute of Nanotechnology puts significant effort into ensuring that the information provided on its news pages is accurate and up-to-date. However, we cannot guarantee absolute accuracy. Consequently, the Institute of Nanotechnology disclaims any and all responsibility for inaccuracy, omission or any kind of deficiency in relation to the news items and articles hosted herein.
- 29 July 2014Nanotechnology and tyres: Greening industry and transport
- 22 July 2014Supporting Recommendations for Future Topics in Horizon 2020
- 17 June 20142014 edition of European NanoSafety Cluster Compendium now online
- 14 May 2014Gold nanoparticles for cancer treatment
- 22 April 2014Irish Materials Research Centre (AMBER) in World First Graphene Innovation
- View All